Forte Biosciences, Inc.
About Forte Biosciences, Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $36.0K
- Net income
- -$69.4M
- Total assets
- $82.8M
- Market cap
- $338.3M
- Operating margin
- -2602.5%
- Net margin
- -2555.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.7M
- Operating expenses
- $70.7M
- Operating income
- -$70.7M
- Income tax
- $1.0M
- Net income
- -$69.4M
- EPS (basic)
- $-4.71
- EPS (diluted)
- $-4.71
Balance sheet
- Total assets
- $82.8M
- Current assets
- $80.6M
- Total liabilities
- $21.8M
- Current liabilities
- $20.8M
- Shareholders’ equity
- $61.0M
Cash flow
- Operating cash flow
- -$50.9M
- Investing cash flow
- $36.2M
- Financing cash flow
- $69.4M
- Net cash flow
- $54.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $338.3M
- EPS (diluted)
- $-4.71
- Shares outstanding
- 21.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $69.4M in FY2019.
- Trading 56% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Forte Biosciences, Inc..
Write a review
News about Forte Biosciences, Inc.
News & sentiment via Polygon.io
